河南翔宇医疗设备股份有限公司 对外担保管理制度 第一章 总则 本制度所称"公司及控股子公司的对外担保总额", 是指包括公司对控股子 公司担保在内的公司对外担保总额与控股子公司对外担保总额之和。 本制度适用于公司及公司的控股子公司。 公司控股子公司应在其董事会或股东会做出决议后及时通知公司履行有关信 息披露义务。 第六条 公司对外担保应当遵循合法、审慎、互利、安全的原则, 严格控制担保风险。 第一条 按照建立现代企业制度的要求, 为进一步完善河南翔宇医疗设备股份有限公 司(以下简称"公司")法人治理结构, 规范公司对外担保行为, 依照《中华人 民共和国公司法》《中华人民共和国证券法》《中华人民共和国民法典》《上市 公司监管指引第 8 号——上市公司资金往来、对外担保的监管要求》《上海 证券交易所科创板股票上市规则》等法律、法规和规范性文件以及《河南翔 宇医疗设备股份有限公司章程》(以下简称"公司章程")的有关规定, 并结合 公司具体情况制定本制度。 第二条 本制度所称对外担保是指公司为他人提供的担保, 包括公司对控股子公司的 担保。 第三条 公司对外担保实行统一管理, 非经公司董事会或股东会批准, 任何人无权以 ...

河南翔宇医疗设备股份有限公司 审计委员会年报工作规程 第一章 总则 第一条 为完善河南翔宇医疗设备股份有限公司（以下简称"公司"）治理 结构，进一步加强公司内部控制建设，充分发挥董事会审计委员会（以下简称"审 计委员会"）对公司年度报告的监督作用，根据法律法规及《公司章程》《信息 披露管理制度》《董事会审计委员会工作细则》等相关规定，结合公司年度报告 编制和披露工作的实际情况，特制订本规程。 第二条 审计委员会在公司年报编制和披露过程中，应当按照有关法律、行 政法规和《公司章程》的要求，认真履行职责，勤勉尽责地开展工作，保证公司 年报信息披露的真实、准确、完整、及时和公平，维护公司整体利益。 第二章 审计委员会年报工作职责及程序 第三条 审计委员会在公司年度财务报告审计过程中，应履行如下主要职责： （一）协调会计师事务所审计工作时间安排； （二）指导内部审计工作，审核公司年度财务信息及会计报表； （三）监督会计师事务所对公司年度审计工作的开展情况，对会计师事务所 审计工作情况进行评估总结； （四）审核公司内控制度，对重大关联交易进行审计； （五）提议聘请或改聘外部审计机构； （一）每个会计年度终结后，审计委员 ...

河南翔宇医疗设备股份有限公司 章 程 二〇二五年十月 | 第一章 | 总测 | | --- | --- | | 第二章 | 经营宗旨和范围 . | | 第三章 | 服 // - | | 第一节 | 股份发行 . | | 第二节 | 股份增减和回购 . | | 第三节 | 服公女 と | | 第四章 股东和股东会 … | | | 第一节 | 股东的一般规定 . | | 第二节 | 控股股东和实际控制人 | | 第三节 | 股东会的一般规定 | | 第四节 | 股东会的召集 | | 第五节 | 股东会的提案与通知 | | 第六节 | 股东会的召开 | | 第七节 | 股东会的表决和决议 . | | 第五章 董事和董事会 | | | 第一节 | 董事的一般规定 . | | 第二节 | 董事么 - | | 第三节 | 独立董事 | | 第四节 | 董事会专门委员会 ………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………… 41 | | 第六章 高级管理人员 . | | | 第七章 财务会计制度 ...

翔宇医疗公告，第三季度营收为1.78亿元，同比增长5.46%；净利润为858.69万元，同比下降48.82%。 前三季度营收为5.37亿元，同比增长6.00%；净利润为4398.15万元，同比下降40.09%。 ...

Core Viewpoint - Xiangyu Medical's stock has shown significant growth this year, with an 88.35% increase, reflecting strong market interest and performance in the rehabilitation medical device sector [1][2]. Financial Performance - For the first half of 2025, Xiangyu Medical reported revenue of 359 million yuan, a year-on-year increase of 6.27%, while net profit attributable to shareholders decreased by 37.50% to 35.39 million yuan [2]. - The company has distributed a total of 277 million yuan in dividends since its A-share listing, with 157 million yuan distributed over the past three years [3]. Stock Market Activity - As of October 30, the stock price reached 54.92 yuan per share, with a market capitalization of 8.787 billion yuan. The stock has seen a trading volume of 83.32 million yuan and a turnover rate of 0.96% [1]. - The stock has experienced a net inflow of 3.06 million yuan from main funds, with significant buying activity from large orders [1]. Shareholder Information - As of June 30, the number of shareholders increased by 6.90% to 6,302, while the average number of circulating shares per person decreased by 6.46% to 25,388 shares [2]. - Hong Kong Central Clearing Limited is noted as a new major shareholder, holding 793,300 shares [3]. Business Overview - Xiangyu Medical, established in March 2002 and listed in March 2021, specializes in the research, production, and sales of rehabilitation medical devices. The revenue composition includes 67.79% from rehabilitation therapy equipment, 22.13% from rehabilitation training equipment, and smaller percentages from other categories [1][2].

Core Insights - The medical device sector experienced a slight increase of 0.37% on October 24, with Mai Lande leading the gains [1] - The Shanghai Composite Index closed at 3950.31, up 0.71%, while the Shenzhen Component Index closed at 13289.18, up 2.02% [1] Medical Device Sector Performance - Top gainers included: - Mai Lande (688273) with a closing price of 41.92, up 6.31%, trading volume of 29,300 hands, and a transaction value of 121 million yuan [1] - Xiangyu Medical (688626) at 53.21, up 6.10%, with a trading volume of 41,100 hands and a transaction value of 216 million yuan [1] - Xiangsheng Medical (688358) at 35.27, up 4.75%, with a trading volume of 38,400 hands and a transaction value of 136 million yuan [1] - Other notable gainers included: - Aohua Endoscopy (688212) at 50.59, up 4.74%, with a transaction value of 225 million yuan [1] - Weisi Medical (688580) at 49.10, up 4.71%, with a transaction value of approximately 99.8 million yuan [1] Decliners in Medical Device Sector - Notable decliners included: - Chenguang Medical (920300) at 17.51, down 8.80%, with a trading volume of 124,000 hands [2] - Toukeng Life (300642) at 22.95, down 5.40%, with a trading volume of 175,700 hands [2] - Haitai New Light (688677) at 48.50, down 5.05%, with a trading volume of 38,800 hands [2] - Other significant decliners included: - Sino Medical (688108) at 28.00, down 4.73%, with a trading volume of 263,700 hands [2] - Tianchen Medical (688013) at 55.66, down 3.98%, with a trading volume of 19,200 hands [2] Capital Flow in Medical Device Sector - The medical device sector saw a net outflow of 654 million yuan from major funds, while retail investors contributed a net inflow of 455 million yuan [2]

Summary of Key Points from Conference Call Records Company and Industry Overview - **Company**: Xiangyu Medical - **Industry**: Brain-Computer Interface (BCI) Technology Core Insights and Arguments - **Focus on Non-Invasive BCI Technology**: Xiangyu Medical specializes in non-invasive brain-computer interface technology, developing five major research and development systems, including BCI acquisition devices, algorithms, and rehabilitation products, with plans to launch related products between late 2025 and 2026 [1][2] - **Applications in Rehabilitation**: The primary applications of Xiangyu Medical's non-invasive BCI products are in rehabilitation, targeting post-operative recovery, high-level paraplegia, Alzheimer's disease, and other clinical challenges through a multi-channel wireless EEG acquisition system and seven algorithms for high-precision signal acquisition and processing [1][4] - **Self-Developed Hardware**: The company has developed a complete set of self-researched chips, electrodes, and acquisition devices, obtaining two Class II medical device registration certificates, which establish a solid foundation and high barriers to entry in the industry [1][5] - **Government Support**: The Ministry of Industry and Information Technology's implementation opinions on promoting innovation in the brain interface industry provide top-level design and reduce policy uncertainty, which Xiangyu Medical is actively leveraging to accelerate product launch processes [1][8] Additional Important Content - **Clinical Applications and Collaborations**: As of the latest statistics, 87 hospitals have applied Xiangyu Medical's BCI products, utilizing various cooperation models, including research project collaborations and the establishment of BCI wards [10] - **Market Commercialization Stage**: The commercialization of BCI products is still in its early stages, with few certified products on the market. Xiangyu Medical plans to launch 27 products in 2025 and potentially 70-80 products in 2026 [9][14] - **Technological Advancements**: The company has achieved breakthroughs in hardware development, including high-precision, high-signal quality acquisition devices, and various electrode models to meet different customer needs [5][11] - **Future Growth and Revenue Projections**: Xiangyu Medical is optimistic about rapid revenue growth in the coming years, with over 100 devices shipped, valued conservatively at 200-300 million yuan, expected to convert into sales revenue depending on certification progress and hospital procurement rhythms [14] Competitive Landscape - **Other Companies in the BCI Field**: Aipeng Medical is also active in the BCI sector, focusing on brain state monitoring systems, insomnia treatment systems, and ADHD behavior management systems, utilizing AI technology to enhance product competitiveness [3][15][17] - **Market Potential for Cognitive Disorders**: The market potential for cognitive disorders, particularly Alzheimer's disease, is significant, with approximately 43.77 million patients in China, indicating a vast opportunity for BCI applications in this area [33] Challenges and Future Directions - **Technical Bottlenecks**: The industry faces challenges such as signal-to-noise ratio, packaging processes, and the need for multi-modal information fusion, which are critical for future development [31][45] - **Regulatory and Market Dynamics**: The current regulatory environment and market dynamics, including the need for certification and pricing strategies, will significantly impact the commercialization and adoption of BCI products [40][41] This summary encapsulates the key points from the conference call records, highlighting the strategic direction, technological advancements, market potential, and challenges faced by Xiangyu Medical and the broader BCI industry.

Core Insights - The rehabilitation equipment industry in China is rapidly growing, with the market size expected to reach approximately 714.6 billion yuan in 2024, an increase of 98.9 billion yuan from 2023 [1][6] - The largest market share within the rehabilitation equipment sector is held by rehabilitation therapy devices at 15%, followed by rehabilitation training devices at 4%, and rehabilitation assessment devices at 1% [6] - The market is projected to grow further, reaching an estimated 815 billion yuan by 2025, driven by an aging population and increasing demand for rehabilitation services [1][6] Industry Definition and Classification - Rehabilitation medical devices are defined as equipment used for the prevention, assessment, treatment, training, or compensation of functional disabilities [3] - The main categories of rehabilitation medical devices include rehabilitation aids, rehabilitation therapy devices, rehabilitation training devices, rehabilitation assessment devices, and other rehabilitation equipment [3] Current Development Status - The rehabilitation equipment market in China is predominantly composed of domestic brands, which account for 97.9% of the market, while imported brands make up about 3% [6] - The industry has seen significant expansion in both market size and application areas due to rapid economic development [6] Industry Chain - The upstream of the rehabilitation equipment industry includes raw materials and software systems, while the midstream involves the manufacturing of rehabilitation devices [8] - The downstream applications primarily serve hospitals, community rehabilitation centers, nursing homes, and other medical institutions catering to populations with functional disabilities [8] Market Environment and Policies - The Chinese government has shown strong support for the rehabilitation equipment industry through various policies aimed at promoting its development, such as the "14th Five-Year" National Health Plan and guidelines for enhancing the welfare of the elderly [11] Competitive Landscape - Major companies in the rehabilitation medical device sector include Yuyue Medical, Kefu Medical, and Xiangyu Medical, with Yuyue Medical leading the market in terms of capital and revenue [12] - The industry exhibits a tiered competitive structure, with leading companies in the first tier and several others in subsequent tiers [12] Future Trends - The rehabilitation equipment industry is expected to experience significant growth opportunities, particularly in home settings, driven by an aging population and increasing chronic disease prevalence [13] - The industry is anticipated to evolve towards high-quality development, supported by technological advancements and favorable government policies [13]

Core Viewpoint - The rapid development of brain-computer interface (BCI) technology in China is driven by policy support, industry promotion, and capital assistance, injecting new momentum into the innovation of the rehabilitation medical industry [1] Group 1: Company Overview - Xiangyu Medical Equipment Co., Ltd. is a leading player in the rehabilitation equipment industry, located in Anyang, Henan Province, which is known for its concentration of over 60 related enterprises [1] - The company has been proactive in BCI technology research and development since 2015, making it one of the earliest entrants in the rehabilitation medical field [2][3] Group 2: Technological Innovation - Xiangyu Medical has launched 13 BCI devices covering various fields such as upper and lower limb rehabilitation training and cognitive impairment assessment, attracting significant market attention [1] - The company aims to transition rehabilitation from passive treatment to active intervention, with BCI technology being a key enabler of this shift [2] Group 3: Research and Development - In the first half of this year, Xiangyu Medical invested 91.147 million yuan in R&D, a year-on-year increase of 38.8%, accounting for 25.39% of its total revenue [4] - The company has established a brain science laboratory and independently develops core components such as chips, electrodes, and algorithms, allowing for integrated control over product development [3][4] Group 4: Market Position and Strategy - Xiangyu Medical has achieved independent development in five key areas of BCI technology, becoming one of the companies with the widest application scenarios in the country [4] - The company is focusing on high-end product development to overcome the challenges of low-end product homogenization and foreign brand dominance in the rehabilitation equipment market [5] Group 5: Future Outlook - By the end of this year, Xiangyu Medical expects to have over 20 BCI products certified, with plans to integrate these products into comprehensive solutions for various clinical scenarios [6] - The company aims to build a "BCI+" rehabilitation industry ecosystem and actively participate in setting industry standards and clinical application norms [8]

Investment Rating - The report suggests focusing on companies with "technical barriers + clinical landing" as the dual main lines for investment, recommending attention to medical scene integrators and leaders in invasive technology [4]. Core Insights - The brain-computer interface (BCI) industry is driven by both policy and technology, with a market expected to grow from $1.2 billion in 2019 to $2 billion in 2023, and projected to reach $7.63 billion by 2029, indicating a compound annual growth rate (CAGR) of 17.5% from 2024 to 2029 [3][24]. - The medical sector is currently the most mature application area for BCI, with 31 clinical trials planned in 2024 covering various diseases, and the integration of medical and consumer applications is expected to create a dual growth curve [3][54]. - The domestic industry chain is becoming more self-sufficient, with significant advancements in invasive BCI technologies, and several regions are expected to form industrial clusters [4][27]. Summary by Sections Industry Overview - BCI technology is a frontier field at the intersection of life sciences and information technology, creating interactive systems between the brain and external devices [14][16]. - The global BCI market is projected to grow significantly, with a forecasted market size of $7.63 billion by 2029, reflecting a CAGR of 17.5% from 2024 to 2029 [24][25]. - The industry is currently in a technology validation phase, with active investment activities, particularly in China, where over 200 financing events have occurred, totaling nearly $2 billion [27][29]. Policy Guidance - The Chinese government has issued several policies to support the BCI industry, aiming for technological breakthroughs by 2027 and the establishment of a robust industrial ecosystem by 2030 [42][43]. - The regulatory framework is evolving, with ongoing efforts to ensure safety, effectiveness, and ethical compliance in BCI technology [45][47]. Clinical Situation - Stroke is identified as the primary indication for BCI applications, with a significant patient population in need of rehabilitation solutions [54][59]. - The number of clinical trials related to BCI is increasing, with 31 trials registered in 2024, indicating a growing interest in the clinical potential of BCI technologies [65][66].